ARID1A

Across TCGA pan-cancer cohorts, ARID1A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARID1A data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARID1A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARID1A expression acts as an unfavorable survival marker, although some lineages such as LSCC and OV show a favorable association.

HNSC, LSCC, and OV are the cancer types where ARID1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.586	0.946	<.001	67	view →
LSCC	DFS	Quartile	All	0.852	0.545	.004	16	view →
OV	DFS	Tertile	All	0.884	0.514	.040	8	view →
CCRCC	DFS	Median	III,IV	0.718	0.447	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARID1A–HNSC (DFS)

Open the HNSC breakdown →